Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bergman v. Caribou Biosciences, Inc. et al
Case Number:
3:23-cv-01742
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
July 01, 2024
Caribou Bio Inks $3.9M Deal In Investors' Cancer Therapy Suit
Caribou Biosciences Inc. has agreed to pay $3.9 million to settle a proposed class action alleging it misled investors about the durability of its most advanced cancer-fighting therapy before and after the gene-editing biotechnology company went public, investors told a California federal judge on Friday.
-
November 16, 2023
Cancer Drug Co. Says Efficacy Talk Didn't Mislead Investors
Gene-editing biotechnology firm Caribou Biosciences Inc. wants a proposed shareholder class action accusing it of misleading investors about the durability of its top cancer-fighting therapy to be dismissed, arguing the investor cannot show the statements were known to be false when they were made.
-
April 12, 2023
Investors Allege Caribou Oversold Cancer Therapy's Promise
Shareholders hit Caribou Biosciences Inc. with a class action Tuesday alleging the gene-editing biotechnology firm misled investors about the durability of its top cancer-fighting therapy leading up to and after its July 2021 initial public offering.